Form 4: Avidity Biosciences' Chief Legal Officer Receives Stock Options and Restricted Stock Units

John B. Moriarty, Chief Legal Officer of Avidity Biosciences, acquired 25,000 shares of common stock and stock options for 160,000 shares on August 1, 2024, as reported in a Form 4 filing with the SEC.

Summary

• On August 1, 2024, John B. Moriarty, the Chief Legal Officer of Avidity Biosciences, acquired 25,000 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs vest in four equal installments on the first four anniversaries of August 1, 2024, contingent upon continuous service to the Issuer.
• Moriarty also acquired stock options for 160,000 shares with an exercise price of $44.57.
• These options vest over four years, with 1/4 vesting on the first anniversary of August 1, 2024, and the remaining vesting monthly thereafter, subject to continuous service.
• Following these transactions, Moriarty directly owns 25,000 shares of common stock and holds options for 160,000 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The vesting schedules suggest a long-term commitment.

Positives

• The grant of RSUs and stock options to the Chief Legal Officer aligns his interests with those of the shareholders.
• The vesting schedules for both the RSUs and stock options incentivize long-term service and commitment to the company.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• Shareholders: Transparency regarding executive compensation.
• Employees: Insight into executive incentives and company performance alignment.

Key Dates